Enhanced proliferation of functionally competent bone marrow cells in different strains of mice treated with swainsonine.
The immunomodulatory alkaloid swainsonine (8alphabeta-indolizidine-1alpha,2alpha,8beta-triol) has potential for overcoming the bone marrow suppressive effects of cancer chemotherapy and radiotherapy. An earlier study showed that multiple doses of swainsonine enhanced bone marrow cellularity in four different strains (C57BL/6; C3H-HEN; Balb/C and DBA-2 mice) of inbred mice which were not exposed to any chemotherapeutic agents or radiation. In vitro assessment of total colony formation capacity of bone marrow cells (BM CFUs) showed a 2- to 8-fold increase in swainsonine-treated mice compared to control mice that were given sham injections of physiological saline. In the current study, we have evaluated the functional competence of the bone marrow cells produced in response to swainsonine treatment of normal healthy mice. In particular, colony forming units-granulocyte-macrophage (CFU-GM), erythroid-burst forming units (BFUe) and CFU-Mix (or CFU-granulocyte-erythrocyte-monocyte-megakaryocyte (CFU-GEMM)) levels, were determined using in vitro assays. The time course of the changes in CFU-GM, BFUe and CFU-Mix (CFU-GEMM) were also followed. Our results demonstrate that swainsonine bolsters the CFU capacity of BM cells without loss of function to levels which are several folds higher than in sham-treated control mice. Swainsonine treatment caused an increase in all lineages of marrow cells without loss of function. This effect was reproduced in all four strains of inbred mice in this investigation. Examination of the peripheral blood did not reveal increase in white blood cells or changes in the hematocrit levels. The long-term effects of swainsonine treatment are not known at present. Nonetheless, swainsonine-induced increase in CFU capacity of bone marrow cells and related cells along the different differentiation paths should find clinical application in cancer treatment with chemotherapeutic agents and/or radiation.
Oredipe
Oladipo A
OA
Department of Pharmacology, Howard University College of Medicine, Washington, DC 20060, USA. ooredipe@howard.edu
Furbert-Harris
Paulette M
PM
Laniyan
Ibrahim
I
Green
William R
WR
White
Sandra L
SL
Olden
Kenneth
K
Parish-Gause
Debra
D
Vaughn
Theresa
T
Griffin
Walter M
WM
Sridhar
Rajagopalan
R
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001854:Bone Marrow Cells / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D006412:Hematopoietic Stem Cells; D007111:Immunity, Cellular / Q000187:drug effects*; D007121:Immunocompetence / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D013045:Species Specificity; D013234:Stem Cells / Q000187:drug effects; D013268:Stimulation, Chemical; D017026:Swainsonine / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D017026:Swainsonine